Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Robert W. Baird

Investment analysts at Robert W. Baird started coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Get Free Report) in a report issued on Friday, Marketbeat.com reports. The firm set an "outperform" rating and a $46.00 price target on the stock. Robert W. Baird's price objective would suggest a potential upside of 78.92% from the stock's previous close.

Several other analysts have also recently issued reports on DYN. Stifel Nicolaus upped their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Piper Sandler reissued an "overweight" rating and set a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer reissued an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and an average target price of $50.42.

Dyne Therapeutics Trading Up 0.4 %

NASDAQ:DYN traded up $0.10 during mid-day trading on Friday, hitting $25.71. The company had a trading volume of 558,345 shares, compared to its average volume of 1,444,530. The business has a fifty day simple moving average of $30.53 and a 200-day simple moving average of $35.24. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -7.11 and a beta of 1.09. Dyne Therapeutics has a 1 year low of $11.51 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 180,046 shares of company stock worth $6,300,265. 20.77% of the stock is owned by insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock valued at $244,755,000 after buying an additional 2,189,339 shares in the last quarter. State Street Corp increased its holdings in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock worth $130,816,000 after buying an additional 440,890 shares during the last quarter. RTW Investments LP raised its position in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after acquiring an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. raised its position in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.